The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COSTEM 2019 | MM: stem cell mobilization regimens with and without plerixafor
Nicolaus Kröger, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses his work on stem cell mobilization regimens with and without plerixafor in multiple myeloma (MM) patients. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.
